01 /What it is
Cagrilintide is a long acting analog of amylin, the 37 amino acid pancreatic peptide that is co secreted with insulin. The molecule is fatty acid modified to extend half life and is studied as a research compound at amylin and calcitonin receptors, typically in combination with Semaglutide (the combination is referred to in the literature as CagriSema).
02 /How it works
In research models, Cagrilintide binds the amylin receptor complex (calcitonin receptor plus a RAMP subunit) on hindbrain neurons and signals through pathways that researchers study in satiety and gastric emptying contexts. The fatty acid side chain mediates albumin binding that extends the active window to once weekly in animal pharmacokinetic studies.
03 /What researchers explore it for
Researchers have explored Cagrilintide in amylin receptor research, in satiety pathway research, and in combination research with Semaglutide and other GLP-1 receptor agonists.
04 /Safety and interactions
Cagrilintide is for laboratory research use only and is not for human consumption. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease.
05 /Research notes
Peptide family: amylin and calcitonin receptor agonists. Frequently compared with the GLP-1 receptor agonist family and studied in combination with Semaglutide. The Apothify library lists Cagrilintide for encyclopedia coverage only because the compound is under active clinical development.
Related peptides
Semaglutide · Liraglutide · Tirzepatide
